Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer
- 30 September 1997
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 66 (3) , 480-486
- https://doi.org/10.1006/gyno.1997.4787
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Salvage Chemotherapy for Epithelial Ovarian CarcinomaGynecologic Oncology, 1994
- Hexamethylmelamine/Altretamine as Second-Line Therapy for Epithelial Ovarian CarcinomaGynecologic Oncology, 1993
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.Journal of Clinical Oncology, 1992
- Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.Journal of Clinical Oncology, 1991
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Phase II Clinical Evaluation of Etoposide (VP-16-213, Vepesid®) as a Second-Line Treatment in Ovarian CancerOncology, 1990
- Hexamethylmelamine as a single second-line agent in ovarian cancerGynecologic Oncology, 1990